Shanta Chawla, M.D. has been appointed vice president of Clinical Development at CytRx Corp. Dr. Chawla has more than 13 years of clinical research, operations, and development experience, with a focus on oncology.
 
Dr. Chawla joins the company from Spectrum Pharmaceuticals, most recently serving as vice president of Clinical R&D, where she selected clinical trial sites and principal investigators, established protocols with the FDA, and prepared FDA filings.
 
“In this new position, Dr. Chawla will play a key role in the management of our upcoming global Phase 3 clinical trial under a Special Protocol Assessment with aldoxorubicin as a second-line treatment for soft tissue sarcomas,” said CytRx executive vice president and chief medical officer Dr. Daniel Levitt. “She has designed and managed large clinical trials in North America and Europe for a range of cancer types, and brings to CytRx a proven ability to meet enrollment targets and work within budget requirements. We are fortunate to have Dr. Chawla join our team as we move into a very exciting and demanding phase of activity.”